71254-63-2

Basic information

• Product Name: 7-METHYL-1,1-DIOXO-1,4-DIHYDRO-2H-1LAMBDA6-BENZO[1,2,4]THIADIAZIN-3-ONE
• Synonyms: 7-METHYL-1,1-DIOXO-1,4-DIHYDRO-2H-1LAMBDA6-BENZO[1,2,4]THIADIAZIN-3-ONE
• CAS NO: 71254-63-2
• Molecular Formula: C₈H₈N₂O₃S
• Molecular Weight: 212.22572
• Mol File: 71254-63-2.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• Density: 1.437g/cm³
• Refractive Index: 1.595
• CAS DataBase Reference: 7-METHYL-1,1-DIOXO-1,4-DIHYDRO-2H-1LAMBDA6-BENZO[1,2,4]THIADIAZIN-3-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 7-METHYL-1,1-DIOXO-1,4-DIHYDRO-2H-1LAMBDA6-BENZO[1,2,4]THIADIAZIN-3-ONE(71254-63-2)
• EPA Substance Registry System: 7-METHYL-1,1-DIOXO-1,4-DIHYDRO-2H-1LAMBDA6-BENZO[1,2,4]THIADIAZIN-3-ONE(71254-63-2)

Safety Data

• Hazardous Substances Data: 71254-63-2(Hazardous Substances Data)

Usage

InChI:InChI=1/C8H8N2O3S/c1-5-2-3-6-7(4-5)14(12,13)10-8(11)9-6/h2-4H,1H3,(H2,9,10,11)

Upstream product

• 1189-71-5 isocyanate de chlorosulfonyle 
• 106-49-0 p-toluidine 
• 380885-39-2 N-(p-toluenyl)-N'-(chlorosulfonyl)-urea 

Downstream Products

• 153439-24-8 C₁₁H₁₄N₂O₅S 
• 1432504-07-8 C₂₁H₂₂F₃N₃O₅S 
• 1432504-06-7 C₁₉H₁₈F₃N₃O₅S 
• 1432504-05-6 C₂₄H₂₀F₃N₃O₅S 
• 1432504-04-5 C₂₁H₂₀F₃N₃O₆S 
• 1432504-03-4 C₂₂H₂₂F₃N₃O₅S 
• 1432504-02-3 C₁₇H₁₃F₃N₂O₆S 
• 1432504-01-2 C₂₁H₂₃BrFN₃O₅S 
• 1432504-00-1 C₁₉H₁₉BrFN₃O₅S 
• 1432503-99-5 C₂₄H₂₁BrFN₃O₅S 
• 1432503-98-4 C₂₁H₂₁BrFN₃O₆S 
• 1432503-97-3 C₂₂H₂₃BrFN₃O₅S 
• 1432503-96-2 C₁₇H₁₄BrFN₂O₆S 
• 1432503-95-1 methyl 2-(7-(diethylcarbamoyl)-1,1-dioxo-2-(2,4,5-trifluorobenzyl)-2H-benzo[e][1,2,4]thiadiazin-4(3H)-yl)acetate 

Relevant articles and documents

"a Sweet Combination": Developing Saccharin and Acesulfame K Structures for Selectively Targeting the Tumor-Associated Carbonic Anhydrases IX and XII

The sweeteners saccharin (SAC) and acesulfame K (ACE) recently entered the topic of anticancer human carbonic anhydrase (CA, EC 4.2.1.1) inhibitors, as they showed to selectively inhibit the tumor-associated CAs IX/XII over ubiquitous CAs. A drug design s

Synthesis and pharmacological activity of N-(2,2-dimethyl-3,4-dihydro-2H-1- benzopyran-4-yl)-4H-1,2,4-benzothiadiazine-3-carboxamides 1,1-dioxides on rat uterus, rat aorta and rat pancreatic β-cells

N-(2,2-Dimethyl-3,4-dihydro-2H-1-benzopyran-4-yl)-4H-1,2, 4-benzothiadiazine-3-carboxamides 1,1-dioxides were prepared and evaluated on rat uterus, rat aortic rings and rat pancreatic β-cells. Pharmacological studies conducted on rat uterus indicated that several of these original hybrid compounds displayed a strong myorelaxant activity. The most active compounds hold a bromine atom at the 6-position of the dihydrobenzopyran ring. Moreover, the compounds failed to display a marked inhibitory effect on insulin secretion and vascular myogenic activity. These features suggest that the 6-bromo compounds could be relatively selective towards the uterine smooth muscle.

Inhibitors of HCV NS5B polymerase: Synthesis and structure-activity relationships of N-1-benzyl and N-1-[3-methylbutyl]-4-hydroxy-1,8-naphthyridon-3-yl benzothiadiazine analogs containing substituents on the aromatic ring

A series of non-nucleoside HCV NS5B polymerase inhibitors based on the N-1-benzyl or N-1-[3-methylbutyl]-4-hydroxy-1,8-naphthyridon-3-yl benzothiadiazine core substituted in the D-ring aromatic moiety have been prepared and evaluated. Aromatic substituents extending from position 7 of the D-ring exhibited excellent potency against both genotypes 1a and 1b.